|A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients.|
|PMID: 20066735 Owner: NLM Status: MEDLINE|
|AIM: To investigate whether probiotic bacteria, given perioperatively, might adhere to the colonic mucosa, reduce concentration of pathogens in stools, and modulate the local immune function.
METHODS: A randomized, double-blind clinical trial was carried out in 31 subjects undergoing elective colorectal resection for cancer. Patients were allocated to receive either a placebo (group A, n = 10), or a dose of 10(7) of a mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) (group B, n = 11), or the same mixture at a concentration of 10(9) (group C, n = 10). Probiotics, or a placebo, were given orally 2 doses/d for 3 d before operation. The same treatment continued postoperatively from day two to day four. Stools were collected before treatment, during surgery (day 0) and 5 d after operation. During the operation, colonic mucosa samples were harvested to evaluate bacterial adherence and to assess the phenotype of dendritic cells (DCs) and lymphocyte subsets by surface antigen expression (flow cytometry). The presence of BB536 and La1 was evaluated by the random amplified polymorphism DNA method with specific polymerase chain reaction probes.
RESULTS: The three groups were balanced for baseline and surgical parameters. BB536 was never found at any time-points studied. At day 0, La1 was present in 6/10 (60%) patients in either stools or by biopsy in group C, in 3/11 (27.2%) in group B, and none in the placebo group (P = 0.02, C vs A). There was a linear correlation between dose given and number of adherent La1 (P = 0.01). The rate of mucosal colonization by enterobacteriacae was 30% (3/10) in C, 81.8% (9/11) in B and 70% (7/10) in A (P = 0.03, C vs B). The Enterobacteriacae count in stools was 2.4 (log10 scale) in C, 4.6 in B, and 4.5 in A (P = 0.07, C vs A and B). The same trend was observed for colonizing enterococci. La1 was not found at day +5. We observed greater expression of CD3, CD4, CD8, and naive and memory lymphocyte subsets in group C than in group A with a dose response trend (C > B > A). Treatment did not affect DC phenotype or activation, but after ex vivo stimulation with lipopolysaccharides, groups C and B had a lower proliferation rate compared to group A (P = 0.04). Moreover, dendritic phenotypes CD83-123, CD83-HLADR, and CD83-11c (markers of activation) were significantly less expressed in patients colonized with La1 (P = 0.03 vs not colonized).
CONCLUSION: La1, but not BB536, adheres to the colonic mucosa, and affects intestinal microbiota by reducing the concentration of pathogens and modulates local immunity.
|Luca Gianotti; Lorenzo Morelli; Francesca Galbiati; Simona Rocchetti; Sara Coppola; Aldo Beneduce; Cristina Gilardini; Daniela Zonenschain; Angelo Nespoli; Marco Braga|
Related Documents :
|20865215 - Bacteriemia during endodontic treatment in relation to the technique of biomechanical p...
21864875 - Evaluation of metoclopramide and ranitidine on the prevention of gastroesophageal reflu...
7900495 - Treatment of acute sigmoid volvulus.
11372795 - New polyethylene glycol laxative for treatment of constipation in adults: a randomized,...
20081225 - The bilag multi-centre open randomized controlled trial comparing ciclosporin vs azathi...
22410245 - Long-term radiographic outcome of nodular bronchiectatic mycobacterium avium complex pu...
|Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't|
|Title: World journal of gastroenterology : WJG Volume: 16 ISSN: 2219-2840 ISO Abbreviation: World J. Gastroenterol. Publication Date: 2010 Jan|
|Created Date: 2010-01-12 Completed Date: 2010-04-08 Revised Date: 2014-05-20|
Medline Journal Info:
|Nlm Unique ID: 100883448 Medline TA: World J Gastroenterol Country: China|
|Languages: eng Pagination: 167-75 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Bifidobacterium / isolation & purification
Colorectal Neoplasms / drug therapy*, microbiology*, pathology
Dose-Response Relationship, Drug
Enterococcus / isolation & purification
Feces / microbiology*
Immunity / physiology*
Intestinal Mucosa / microbiology*, pathology
Lactobacillus / isolation & purification
Lymphocyte Subsets / pathology
Probiotics / therapeutic use*
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Next Document: Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patien...